AI Tool for Breast Cancer Diagnosis: Collaboration Between Clearview Diagnostics and Dr. Susan Love Research Foundation

Share Article

Clearview Diagnostics pledges portion of proceeds of AI-based breast cancer triage tool to Dr. Susan Love Research Foundation

It is great to see our technology being applied to real-world applications that can help make a difference for women’s healthcare worldwide.

Clearview Diagnostics has developed artificial intelligence (AI) technology for breast cancer diagnosis using low-cost, portable ultrasound imaging devices. This computer-aided diagnosis triage product (Clearview CADt) has the potential to save women’s lives in parts of the world that do not have access to routine breast cancer screening or diagnosis. This project is a collaborative effort with Dr. Susan Love and Dr. Susan Love Research Foundation (the Foundation) and is being funded by a $4 million grant from the National Institutes of Health (NIH), National Cancer Institute (NCI).

A portion of the proceeds of every sale of the Clearview CADt product has been pledged to the Foundation in recognition of their impactful work on this project. Dr. Susan Love Research Foundation is dedicated to achieving a future without breast cancer by engaging the public and the scientific communities in innovative research. Susan Love, Chief Visionary Officer of the Foundation, stated, “This product has the potential to help women in low- and middle-income countries that currently have limited access to healthcare and breast cancer diagnosis. We are grateful to Clearview for their generosity and partnership on this important project.”

Christine Podilchuk, CEO of Clearview Diagnostics, said that “It has been great working with the Foundation under the NIH Grant and we are really looking forward to getting the product into the market during Phase II of the Grant”. Clearview Diagnostics is focused on developing the next generation of AI tools to help diagnose various diseases including breast cancer. The company has expertise in artificial intelligence techniques including deep learning and neural networks and applying these methods to machine vision. This AI platform can work with images captured on high-end ultrasound images devices as well as low-cost portable units making it a compelling solution for resource-limited parts of the world. The Founder, Rick Mammone, stated “We have been able to show a reduction in false positives by 50% while maintaining the cancer detection rate of skilled radiologists. It is great to see our technology being applied to real-world applications that can help make a difference for women’s healthcare worldwide.”

Mammography is the gold standard for breast cancer screening and has been shown to reduce the mortality rate of breast cancer but low- and middle-income countries do not always have access to mammography, diagnostic imaging or highly trained healthcare professionals. The mortality rate due to breast cancer is also much higher in these parts of the world. Clearview’s goal is to help close this gap.

About Clearview Diagnostics, Inc.
Clearview Diagnostics is dedicated to advancing healthcare through innovative artificial intelligence (AI) technology. The company’s state-of-the-art machine learning technology is designed to assist healthcare professionals in disease diagnosis in order to improve patient outcome, reduce overall healthcare costs and make medical image diagnosis accessible worldwide. Clearview’s initial focus is on breast cancer diagnosis and the company plans to expand its AI platform to other diseases and imaging modalities. Clearview Diagnostics is headquartered in Piscataway, NJ. For more information, please visit http://www.clearviewdiagnosticsinc.com

About Dr. Susan Love Research Foundation
Dr. Susan Love Research Foundation challenges the status quo to achieve a future without breast cancer and improve the lives of people impacted by it now through education and advocacy. We drive collaborative cutting-edge research on cause and prevention with nontraditional partners, bring to light the collateral damage of treatment and seek ways to diminish it, and interpret science to empower patients.

We drive progress by being fast, flexible, and project-based. We actively engage the public in our scientific research to ensure that it produces accurate and meaningful results.

Dr. Susan Love Research Foundation has received a 4-star Charity Navigator rating for four consecutive years, putting it in the top 12% of rated charities in terms of fiscal performance, accountability, and transparency. The Foundation is also a GuideStar Exchange Silver Level participant and a member of the Better Business Bureau Wise Giving Alliance.
Dr. Susan Love Research Foundation, and its more than 378,000 volunteers nationwide, invite you become part of a movement to engage the public in breast cancer research with the goal of eradicating the disease once and for all. To learn more and show your support, visit http://www.drsusanloveresearch.org.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

William Hulbert, VP of Product Development
@clearviewdiag
Follow >
ClearView Diagnostics Inc.
since: 07/2014
Like >
Visit website